It's typically feast or famine when it comes to biotech stocks, but one big winner can more than make up for a bunch of losers. The secret is finding well-run companies delivering high-quality drugs before the market finds them.

Of course, that's easier said than done, and some biotech companies are already beyond their high-growth stage. Nevertheless, in that spirit, we'll use the aggregate intelligence of the 105,000-plus investors participating in Motley Fool CAPS to find biotech stocks that the community likes -- those with four- and five-star ratings. The community's approval could be a sign that further research is in order.

Here are five such stocks:

Company

Market Cap

% CAPS All-Star Bulls

CAPS Rating
(Out of 5)

CAPS Research

Amgen (NASDAQ:AMGN)

$46.8 B

94.3%

****

AMGN

Genentech (NYSE:DNA)

$77.7 B

96.3%

****

DNA

Genzyme (NASDAQ:GENZ)

$17.4 B

95.1%

*****

GENZ

ViroPharma (NASDAQ:VPHM)

$697 M

98.3%

*****

VPHM

Gilead Sciences (NASDAQ:GILD)

$49.0 B

97.6%

*****

GILD

Source: Motley Fool CAPS, as of June 11, 2008.

Come and join us on CAPS to learn more about these and countless other interesting stock ideas. Sign up for free.